MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor…
MaaT PharmaNovember 5, 2025
June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization…
MaaT PharmaJune 19, 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA…
MaaT PharmaJune 13, 2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency…
MaaT PharmaJune 2, 2025
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive…
MaaT PharmaMay 13, 2025
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…
MaaT PharmaApril 28, 2025
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033…
MaaT PharmaApril 8, 2025
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaApril 4, 2025
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…
MaaT PharmaMarch 31, 2025
